LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients
CONCLUSIONS: Subclassification of IR prostate cancer into FIR and UIR subcategories appears mandatory. For FIR patients, outcomes after BT monotherapy were acceptable. However, clinical failure after 125J-LDR-BT in UIR patients was notably increased, suggesting that BT monotherapy was less successful in this risk group. In contrast, the outcome in UIR patients after CRT was excellent.PMID:37714724 | DOI:10.1016/j.urolonc.2023.08.007
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Andreas Boehle Dorothea Zywietz Irina Robrahn-Nitschke Achim Lusch Inke R K önig Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | History of Medicine | Prostate Cancer | Radiation Therapy | Urology & Nephrology